

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6587123

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED	10/16/2020
RECEIVING PARTY DATA		
Name:	CHARLES RIVER LABORATORIES, INC.	
Street Address:	251 BALLARDVALE STREET	
City:	WILMINGTON	
State/Country:	MASSACHUSETTS	
Postal Code:	01887	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16639486
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2023712600	
Email:	BNCOMBS@sternekessler.com, jmccoy@sternekessler.com, ttpssecretary2@sternekessler.com, jyando@sternekessler.com	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
Address Line 1:	1100 NEW YORK AVENUE NW	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	4559.0010001	
NAME OF SUBMITTER:	JOSHUA G. MCCOY, REG. NO. 70307	
SIGNATURE:	/Joshua G. McCoy/	
DATE SIGNED:	03/05/2021	
Total Attachments: 3		
source=[4559.0010001] Assignment - Charles River DR to CRL_signed#page1.tif		
source=[4559.0010001] Assignment - Charles River DR to CRL_signed#page2.tif		
source=[4559.0010001] Assignment - Charles River DR to CRL_signed#page3.tif		

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **Charles River Discovery Research Services UK Limited**, a corporation organized and existing under the laws of the United Kingdom and having an office and place of business at Robinson Building Chesterford Research Park, Little Chesterford, Saffron Walden, England, CB10 1XL, United Kingdom (hereafter referred to as the "Assignor"), hereby sells and assigns and/or confirms sale and assignment to **Charles River Laboratories, Inc.**, a corporation formed under the laws of Delaware, having an office and place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (hereafter referred to as the "Assignee"), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in the invention(s) known as **TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS** for which application(s) for patent in the United States of America (also known as United States Application No. 16/639,486, which is the U.S. national phase of International Application No. PCT/EP2018/073872, International Filing Date September 5, 2018, which claims priority to European Application No. 17189933.9, filed September 7, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application(s) listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application(s) listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and

interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Assignor hereby represents that the Assignor understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are NOT the legal representatives of, and attorneys for, the Assignor.

SIGNED on behalf of the said ASSIGNOR,

CHARLES RIVER DISCOVERY RESEARCH
SERVICES UK LIMITED

By: 

Name:

SARAN PRICE

Title:


DIRECTOR

Date:

16 OCTOBER 2020

SIGNED on behalf of the said ASSIGNEE,

CHARLES RIVER LABORATORIES, INC.

By: 
Name: JACKIE MACRITCHIE
Title: SENIOR MANAGING DIRECTOR
Date: 19 OCTOBER 2020

15254004.1